Lumateperone in schizophrenia: a profile of its use

AbstractOral lumateperone (Caplyta®) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults in the USA. As a mechanistically novel agent that selectively and simultaneously modulates serotonin, dopamine, and glutamate neurotransmission, it offers a new option for the management of this severe and debilitating mental disorder. Across three phase 2 or 3 studies in patients with an acute exacerbation of schizophrenia, double-blind treatment with lumateperone 42  mg/day for 4–6 weeks significantly improved psychotic symptoms and global disease severity compared with placebo. Additionally, open-label treatment with lumateperone for up to 1 year was associated with continuous improvements in psychotic symptoms in patients with stable schizophrenia switch ed from standard-of-care antipsychotics. Lumateperone therapy is generally well tolerated, with a placebo-like and comparatively favourable safety profile with respect to motor, metabolic and cardiovascular issues.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research